𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prognostic factors of Chinese patients with primary pulmonary non-Hodgkin’s lymphoma: the single-institute experience in Taiwan

✍ Scribed by Yu-Hui Hu; Liang-Tsai Hsiao; Ching-Fen Yang; Tzeon-Jye Chiou; Jin-Hwang Liu; Jyh-Pyng Gau; Chueh-Chuan Yen; Teh-Ying Chou; Wen-Hu Hsu; Po-Min Chen; Cheng-Hwai Tzeng

Publisher
Springer
Year
2009
Tongue
English
Weight
148 KB
Volume
88
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic factors for patients with dif
Prognostic factors for patients with diffuse large cell or immunoblastic non-Hodgkin's lymphomas: Experience of the non-Hodgkin's lymphoma pathologic classification project
✍ Simon, Richard ;Durrleman, Sylvain ;Hoppe, Richard T. ;Bonadonna, Gianni ;Bloomf 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 678 KB

## Abstract Prognostic factors for long‐term survival of 312 patients with diffuse large cell or immunoblastic non‐Hodgkin's lymphoma are presented based on analysis of the multi‐institution clinicopathologic study sponsored by the National Cancer Institute. At the time of analysis, 75% of the pati

Application of the international prognos
Application of the international prognostic index in a study of chinese patients with non-hodgkin's lymphoma and a high incidence of primary extranodal lymphoma
✍ Tony S. Mok; Joyce Steinberg; Anthony T. Chan; Winnie M. Yeo; P. Hui; Thomas W. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 3 views

## Background: Chemotherapy containing anthracycline is the standard initial treatment for aggressive non-hodgkin's lymphoma (nhl), and the international prognostic index (ipi) is widely accepted as the standard tool for determining the prognosis of patients with this disease. however, the data on

CEOP treatment results and validity of t
CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma
✍ C. S. Chim; Y. L. Kwong; A. K. W. Lie; C. K. Lee; R. Liang 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 2 views

From 1991 to 1997, we have treated 78 newly diagnosed patients with aggressive non-Hodgkin's lymphoma with a modified CHOP regimen in which epirubicin (60 mg/m 2 ) was used in place of doxorubicin (50 mg/m 2 ), i.e. CEOP (cyclophosphamide, epirubicin, vincristine and prednisolone). The median age wa